News & Events
Genetic Analysis to attend DDW congress in Chicago (opens in a new tab)
OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 – May 5 2026. The company will use the meeting to highlight its upcoming product, GA-map® IBD Precision Dx, a next-generation diagnostic solution for persona…
Nestlé Health Science Joins Microbiome Therapeutics Innovation Group
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 (opens in a new tab)
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live biotherapeutics in shaping outcomes in IBD and immunocompromised patients CAMBRIDGE, Mass., April…
Endpoints – Women’s health biotech Freya Biosciences advances microbial therapy for IVF implantation failure (opens in a new tab)
View article…
Freya Biosciences announces positive Phase 1 first-in-human data with FB301 for IVF-related embryo implantation failure (opens in a new tab)
Freya Biosciences (“Freya” or “the Company”), a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces positive topline results from its Phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain Lactobacillus consortium develo…
Seres Therapeutics to Present at CARB-X Investor Day (opens in a new tab)
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical…
Bio International Convention 2026 (opens in a new tab)
Bio International Convention 2026 The post Bio International Convention 2026 appeared first on MaaT Pharma .…
Kempen Life Sciences Conference 2026 (opens in a new tab)
Kempen Life Sciences Conference 2026 The post Kempen Life Sciences Conference 2026 appeared first on MaaT Pharma .…
Investor Access Event 2026 (opens in a new tab)
Investor Access Event 2026 The post Investor Access Event 2026 appeared first on MaaT Pharma .…
April 1, 2026: Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population – Cancer Network (opens in a new tab)
To read the article, click here! The post April 1, 2026: Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population – Cancer Network appeared first on MaaT Pharma .…
Nature – Voices of biotech leaders (opens in a new tab)
View article…
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (opens in a new tab)
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026 Seres operational focus on advancing live biotherapeutic programs for inflammatory and…
Genetic Analysis AS launches AInsight for AI-assisted interpretation of GA-map® Dysbiosis Test results (opens in a new tab)
OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test AInsight (“AInsight”), an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of micro…
Publication of year-end report 2025 (opens in a new tab)
OSLO, NORWAY – February 27, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the year-end report for 2025. The report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO of Genetic Analysis, comments: “The fourth quarter…
Clarification regarding the publication date of the year-end report 2025 (opens in a new tab)
OSLO, NORWAY – February 26, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that the year-end report for 2025 will be published on Friday, 27 February 2026. The Company’s financial calendar for 2025 was included in the interim report for the first quarter of 2025, in which it was stated that the year-end re…
Scrip – Scrip Asks… What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances (opens in a new tab)
View article…
Genetic Analysis AS further strengthens IP portfolio with patent approval in the United States (opens in a new tab)
OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled “METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S”, strengthens t…
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases (opens in a new tab)
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing…
Microbiome Dx Genetic Analysis announces important patent approval enhancing the use of GA-map® in Canada (opens in a new tab)
OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important patent application CA2980637) has now been allowed for grant in Canada. The important patent entitled “METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique alg…
Nature – Culturing microbiome therapeutics with big data (opens in a new tab)
View article…